Wegener T, Wagner H
Consulting Herbal Medicinal Products, Zeisigstrasse 9, 33378 Rheda-Wiedenbrück, Germany.
Phytomedicine. 2006;13 Suppl 5:20-35. doi: 10.1016/j.phymed.2006.07.001. Epub 2006 Aug 22.
The therapeutic equivalence of the multi-herbal drug combination STW 5 (Iberogast) with two synthetic standard drugs can be explained by an additive or overadditive pharmacological synergism. A review of the different chemical constituents contained in this fixed combination of nine herbal drug extracts and their dominant mechanisms of action shows that they correlate very well with the clinically relevant overall pharmacological profile of the multi-herbal drug combination. This comprises modulatory effects on gastro-intestinal motility, anti-inflammatory action, inhibitory effects on gastric acid production and anti-oxidative and radical-inhibiting properties. As a multi-drug preparation with a multitude of therapeutic targets relevant in functional gastrointestinal diseases, its pharmacological profile of action in accordance with the multi-target principle.
多草药组合药物STW 5(伊贝戈斯特)与两种合成标准药物的治疗等效性可以通过相加或超相加的药理协同作用来解释。对这种由九种草药提取物组成的固定组合中所含不同化学成分及其主要作用机制的综述表明,它们与该多草药组合药物临床相关的整体药理特性非常吻合。这包括对胃肠动力的调节作用、抗炎作用、对胃酸分泌的抑制作用以及抗氧化和自由基抑制特性。作为一种具有多种与功能性胃肠疾病相关治疗靶点的多药制剂,其药理作用特性符合多靶点原则。